Publications & Presentations

Name: CNS Pharmaceuticals
Price range: $

Publications and Presentations

26 July, 2024

Pediatric Blood Cancer

A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

By: Deanna Mitchell, Genevieve Bergendahl, William Ferguson, William Roberts, et. al.

TPI 287

Download PDF

26 July, 2024

Final Results from the Dose-Escalation Stage of a Phase 1/2 Trial of Tpi 287, a Brain Penetrable Microtubule Inhibitor, Plus Bevacizumab in Patients with Recurrent Glioblastoma

By: S. Goldlust, L. Nabors, III, P. Duin, N. Mobile, T. Benkers, et. al.

TPI 287

Download PDF

26 July, 2024

JAMANeurology

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome

TPI 287

Download PDF

26 July, 2024

TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

By: Daniel P. Fitzgerald, David L. Emerson, Yongzhen Qian, et. al.

TPI 287

Download PDF

18 July, 2024

Investor Presentation July 2024

Download PDF

11 August, 2023

2023 SNO/ASCO CNS Cancer Conference

A Randomized, Controlled Trial Of Berbubicin, A Novel Topoisomerase II Inhibitor, After First-Line Therapy For Glioblastoma Multiforme (GBM): Updated Results

By: Z. Muzyczenko (1), S. Silberman (1), S. Hsu (2), D. Picker (1) (1) CNS Pharmaceuticals, Houston, TX, (2) Memorial Hermann Texas Medical Center, Houston, TX,

Berubicin (Recurrent GBM)

Download PDF

There are no publications that match the selected filters.